Understanding the AllTrials Campaign: Its Progress, Impact, and Ongoing Challenges

What Is the AllTrials Campaign and Why Was It Launched?

Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.

The core slogan, “All Trials Registered. All Results Reported.”, crystallized the campaign’s demands for better transparency, improved access to data, and global policy reform. The concern was not academic—non-publication of trial data leads to evidence gaps in medicine, flawed systematic reviews, biased clinical guidelines, and ultimately, suboptimal patient care.

Founding Members and Their Vision

The campaign’s founding members were influential: Cochrane brought its evidence synthesis legacy; BMJ added editorial authority; and Ben Goldacre, through Bad Pharma, revealed pharmaceutical industry shortcomings. The mission was clear:

• Ensure that all clinical trials are registered in a public database before patient recruitment begins
• Mandate reporting of all trial results, regardless of outcomes
• Encourage retrospective registration and disclosure of past trials
• Push for enforceable legislation across jurisdictions

The campaign filled a void left by slow-moving policy, calling out both public institutions and private sponsors for failing to disclose complete data sets.

Milestones Achieved by the Campaign

The AllTrials campaign has achieved significant global visibility and policy impact over the last decade:

• Over 750 organizations signed the AllTrials petition, including medical societies, research funders, and ethics boards
• EMA’s Policy 0070 and EU Clinical Trial Regulation (EU CTR 536/2014) emerged around the same period, supporting proactive disclosure
• Tools like the FDAAA TrialsTracker were developed to monitor sponsor compliance
• Major journals like The Lancet and BMJ made trial registration a prerequisite for publication

Some companies, such as GSK and Johnson & Johnson, pledged to publish trial results proactively. The UK Health Research Authority (HRA) enforced reporting of all trials approved after 2018.

Public Engagement and Open Data Advocacy

Beyond the policy sphere, AllTrials galvanized public support with a petition that received more than 90,000 signatures globally. This grassroots activism sent a clear message to sponsors and regulators: society demands accountability.

The campaign also aligned itself with broader open data and open science movements, promoting reusable datasets and transparency across disciplines. Many academic institutions were prompted to retrospectively register trials and update their result disclosure practices to avoid reputational harm.

Academic Impact and Journal Response

The campaign influenced academic policy significantly. The International Committee of Medical Journal Editors (ICMJE) reinforced its position on trial registration as a publication condition. Guidelines like CONSORT were updated to emphasize complete and timely results disclosure. Systematic reviews began flagging risk of bias due to missing data more aggressively.

Studies also started evaluating transparency metrics. For instance, a PLOS Medicine analysis in 2020 showed that trial reporting among top-tier research institutions improved post-AllTrials, though gaps remain in smaller, investigator-initiated studies.

Challenges and Barriers to Full Compliance

Despite its success, the campaign faces key barriers:

• Enforcement is weak – Legal penalties for non-compliance remain rare outside the U.S.
• Legacy data is inaccessible – Pre-2007 trials remain largely unpublished, and efforts to retrieve those datasets are underfunded
• Resource gaps at small sponsors – Investigator-led trials often lack administrative support for registration and reporting
• Lack of harmonization – Registries like ClinicalTrials.gov, EU CTR, and ICTRP differ in their formats, making global compliance complex

Efforts to address these gaps continue, with transparency advocates lobbying for tougher laws and better sponsor accountability scorecards. Projects like ClinicalStudies.in are helping train institutions in practical compliance tools and global registry management.

Ongoing Monitoring and Compliance Tools

Transparency monitoring has evolved with technology. Platforms like TranspariMED, EU TrialsTracker, and WHO’s ICTRP now offer dashboards to benchmark disclosure by sponsor, country, and funder. Some regulators have started naming and shaming non-compliant institutions, creating reputational incentives for transparency.

Meanwhile, institutions like PharmaValidation.in are developing SOPs and compliance templates for consistent reporting, reducing administrative burden on research sponsors.

Conclusion: A Campaign That Reshaped Clinical Research Norms

The AllTrials campaign permanently changed how clinical research is conducted, reviewed, and disseminated. From patient advocacy to policy reform and journal mandates, the campaign has made a lasting mark.

However, transparency is a continuous journey. The next decade will require stricter enforcement, smarter registries, and full data accessibility—especially in underrepresented regions. The AllTrials legacy remains a blueprint for future movements fighting for ethical, evidence-based science in public health.

To explore global guidelines aligned with AllTrials values, visit the ICH Quality Guidelines and related transparency publications from PharmaRegulatory.in.

Learning from the Biggest Trial Registry Failures in Pharma

Introduction: When Registry Compliance Goes Wrong

Clinical trial registries such as ClinicalTrials.gov are foundational for transparency and public trust in pharmaceutical research. However, even top-tier pharma companies and academic institutions have failed to meet their legal obligations under FDAAA 801 and other global guidelines. These failures lead to reputational damage, regulatory sanctions, and scientific setbacks. In this article, we will explore real-world examples of high-profile trial registration failures, dissect what went wrong, and outline the lessons clinical teams must learn to avoid repeating history.

Each case study underscores the critical role of proactive planning, cross-functional coordination, and GCP-aligned SOPs. Noncompliance is not always malicious—but ignorance or poor processes are no defense in the eyes of regulators.

Case Study 1: GSK Avandia and the Ghost Registry

Background: GlaxoSmithKline’s diabetes drug, Avandia, was implicated in increased cardiovascular risks. What amplified the backlash was the revelation that key trial results had not been made public on ClinicalTrials.gov, despite regulatory expectations.

Findings:

• At least 6 supporting trials were unregistered or lacked published results.
• Congressional investigations found that adverse outcomes were downplayed or unpublished.
• GSK eventually committed to creating an open-access results portal following public and legal pressure.

Impact: GSK paid over $3 billion in fines (including registry and data integrity issues), and Avandia was pulled from multiple markets.

Case Study 2: NIH Audit of Academic Institutions

Background: In 2019, the NIH conducted an audit of major U.S. universities’ compliance with trial registration and results reporting. The audit revealed that fewer than 40% of eligible trials had timely results posted on ClinicalTrials.gov.

Failures Observed:

• Principal Investigators misunderstood FDAAA obligations.
• Institutional oversight committees lacked registry SOPs.
• Many results submissions failed automated validation checks.

Response: NIH threatened to freeze funding unless institutions improved compliance systems. This spurred the development of central registration offices in many universities.

Case Study 3: Sanofi and Delayed Pediatric Trial Disclosure

Background: Sanofi conducted a pediatric asthma trial in Europe, with sites in France and Germany. Although the trial concluded in 2017, the results were not posted until late 2020.

Key Issues:

• Delays were attributed to internal team transitions and confusion over EU vs U.S. reporting standards.
• EMA flagged the trial in a public update on noncompliance with the Paediatric Regulation.
• Parent advocacy groups criticized the opacity around safety data.

Lessons: Global companies must harmonize registration SOPs across geographies. EU Clinical Trials Regulation and U.S. FDAAA 801 timelines differ but must both be met.

Case Study 4: CRO-Induced Registry Lapse

Context: A midsize sponsor outsourced registration responsibilities to a CRO under a functional service model. The trial started in 2019 and was monitored across 4 countries.

Failure Point:

• The CRO created the ClinicalTrials.gov record but failed to update the Primary Completion Date for 14 months.
• As a result, results were not posted within the required 12-month window.
• FDA issued a notice of noncompliance, and the sponsor faced penalties despite the CRO agreement.

Takeaway: Sponsors retain final accountability for registration, even when delegated. Regular QA checks and registry KPIs are non-negotiable.

Case Study 5: FDA Warning Letter to Device Manufacturer

Scenario: In 2022, the FDA issued a warning letter to a U.S.-based medical device company following a BIMO inspection. The root cause: failure to register a pivotal device trial initiated in 2020.

• Observation: Despite IRB approval and subject enrollment, the company had no ClinicalTrials.gov entry.
• Defense: The company argued that they misunderstood whether the trial met ACT criteria.
• FDA Response: Intent to commercialize and trial structure met ACT definitions. Warning issued.

Lesson: The applicability checklist must be reviewed for every trial. Regulatory Affairs and QA must confirm ACT status and file a documented justification—even for non-applicable trials.

Case Study 6: Journal Retraction for Unregistered Oncology Study

Event: An oncology research team published a Phase II trial in a high-impact journal. Post-publication, an academic whistleblower noted that the trial lacked ClinicalTrials.gov registration.

• The journal issued a retraction after confirmation.
• The corresponding author cited “oversight” and no intent to mislead.
• However, the journal adhered to ICMJE policy requiring prospective registration.

Outcome: The institution’s IRB mandated retraining on trial transparency. The PI’s future publications were delayed due to credibility loss.

To prevent such issues, refer to registration SOPs and ICH E6(R2) compliance guidelines at PharmaRegulatory.in.

Case Study 7: Sponsor Rescue Using Retrospective Registry Strategy

Context: A sponsor discovered post-enrollment that one of their Phase III trials was not registered due to internal miscommunication. Instead of panicking, they adopted a transparent retrospective approach:

• Registered the trial within 30 days of discovery with full disclosure of delay
• Included detailed note-to-file and protocol amendment history
• Communicated openly with journals and regulators
• Flagged the issue as a CAPA topic across related SOPs

Result: The journal allowed publication citing honest error, and FDA did not issue penalties due to prompt disclosure and lack of data suppression intent.

This case highlights how transparency and speed can limit damage from compliance lapses. Build an internal registry deviation policy for such scenarios.

Preventive Tips from the Field

• ✅ Implement automated reminders for trial registration deadlines
• ✅ Include registry requirements in kickoff checklists and site initiation visits (SIVs)
• ✅ Link ClinicalTrials.gov task ownership to a named role in TMF
• ✅ Use dashboards to flag overdue results entries across multiple trials
• ✅ Audit registry compliance quarterly as part of QA oversight

For sample registry SOP templates and audit checklists, explore PharmaSOP.in.

Conclusion

High-profile registration failures remind us that transparency isn’t optional—it’s a core obligation in modern clinical research. Whether you’re a sponsor, CRO, or academic site, your clinical credibility hinges on timely, accurate, and complete registry submissions.

Audit your internal processes, train your teams, and treat registration compliance as seriously as protocol deviations or SAE reporting. The risks of ignoring registry obligations—legal, ethical, scientific—are too large to ignore.

To stay updated on evolving global trial disclosure laws and avoid repeating past mistakes, follow regulatory updates from EMA and explore trial quality case studies on ClinicalStudies.in.